| Detected | Trial | Change |
|---|---|---|
| 2026-07-31 | NCT07424833 A Study of APG-3288 in Relapsed/Refractory Blood Cancers |
Recruitment opened |
| 2026-07-31 | NCT07424833 A Study of APG-3288 in Relapsed/Refractory Blood Cancers |
Trial sites expanded: 2 -> 6 locations |
| 2026-07-29 | NCT06319456 A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy… |
Trial sites expanded: 6 -> 10 locations |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06423911 | Study of Olverembatinib (HQP1351) in Patients With CP-CML | Chronic Myeloid Leukemia | Recruiting |
| NCT06641414 | Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With… | Higher-risk Myelodysplastic Syndrome | Recruiting |
| NCT06389292 | A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of… | Acute Myeloid Leukemia | Recruiting |
| NCT06051409 | A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1) | Ph+ ALL | Recruiting |
| NCT06104566 | Global Trial in APG2575 for Patients With CLL/SLL | CLL/SLL | Recruiting |
| NCT06640361 | A Study of Olverembatinib in SDH-deficient GIST. | GIST | Recruiting |
| NCT06319456 | A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy… | CLL/SLL | Recruiting |
| Phase 2 | |||
| NCT04496349 | A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects… | T-Prolymphocytic Leukemia | Recruiting |
| NCT05147467 | Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL | Chronic Lymphocytic Leukemia | Recruiting |
| Phase 1/2 | |||
| NCT04785196 | APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or… | Liposarcoma | Recruiting |
| NCT04494503 | Study of APG2575 Single Agent and Combination Therapy in Patients With… | Chronic Lymphocytic Leukemia | Recruiting |
| NCT06182969 | A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus. | SLE | Recruiting |
| NCT04501120 | Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients… | Relapsed/Refractory Acute Myeloid Leukaemia | Recruiting |
| NCT03611868 | A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With… | Unresectable or Metastatic Melanoma or Advanced Solid Tumors | Active, Not Recruiting |
| Phase 1 | |||
| NCT04275518 | A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine… | Acute Myeloid Leukemia (AML) | Recruiting |
| NCT05701306 | APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory… | Neuroblastoma | Recruiting |
| NCT04215809 | Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for… | CLL/SLL | Recruiting |
| NCT04260022 | Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL | Leukemia, Myeloid, Chronic | Recruiting |
| NCT07282093 | Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment | Pharmacokinetic | Recruiting |
| NCT03594422 | A Study of HQP1351 in Patients With GIST or Other Solid Tumors | Gastrointestinal Stromal Tumor (GIST) | Recruiting |
| NCT05773586 | A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of APG-5918. | Anemia | Recruiting |
| NCT06687070 | APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant… | Platinum-resistant Recurrent Ovarian Cancer | Recruiting |
| NCT03917043 | APG-2449 in Patients With Advanced Solid Tumors | Advanced Solid Cancer | Recruiting |
| NCT07424833 | A Study of APG-3288 in Relapsed/Refractory Blood Cancers | Relapsed/Refractory Hematological Malignancies | Recruiting |
| NCT04001777 | A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients | EGFR Positive Non-small Cell Lung Cancer | Active, Not Recruiting |